دراسة تتوصل إلى أن لقاح كوفيد-19 من فايزر ينتقل إلى خلايا الكبد ويتحول إلى حمض نووي دي إن إيه- كل يوم يكتشف أن اللقاحات لا فائدة منها ومع هذا مصرين على إعطائها للناس ونحن كالعادة تابعين

 

Pfizer’s COVID-19 Vaccine Goes Into Liver Cells and Is Converted to DNA: Study

BY MEILING LEE TIMEMARCH 1, 2022 PRINT

The messenger RNA (mRNA) from Pfizer’s COVID-19 vaccine is able to enter human liver cells and is converted into DNA, according to Swedish researchers at Lund University.

The researchers found that when the mRNA vaccine enters the human liver cells, it triggers the cell’s DNA, which is inside the nucleus, to increase the production of the LINE-1 gene expression to make mRNA.

The mRNA then leaves the nucleus and enters the cell’s cytoplasm, where it translates into LINE-1 protein. A segment of the protein called the open reading frame-1, or ORF-1, then goes back into the nucleus, where it attaches to the vaccine’s mRNA and reverse transcribes into spike DNA.

Reverse transcription is when DNA is made from RNA, whereas the normal transcription process involves a portion of the DNA serving as a template to make an mRNA molecule inside the nucleus.

“In this study we present evidence that COVID-19 mRNA vaccine BNT162b2 is able to enter the human liver cell line Huh7 in vitro,” the researchers wrote in the study, published in Current Issues of Molecular Biology. “BNT162b2 mRNA is reverse transcribed intracellularly into DNA as fast as 6 [hours] after BNT162b2 exposure.”

BNT162b2 is another name for the Pfizer-BioNTech COVID-19 vaccine that is marketed under the brand name Comirnaty.

The whole process occurred rapidly within six hours. The vaccine’s mRNA converting into DNA and being found inside the cell’s nucleus is something that the Centers for Disease Control and Prevention (CDC) said would not happen.

“The genetic material delivered by mRNA vaccines never enters the nucleus of your cells,” the CDC said on its web page titled “Myths and Facts about COVID-19 Vaccines.”

This is the first time that researchers have shown in vitro or inside a petri dish how an mRNA vaccine is converted into DNA on a human liver cell line, and is what health experts and fact-checkers said for over a year couldn’t occur.

The CDC says that the “COVID-19 vaccines do not change or interact with your DNA in any way,” claiming that all of the ingredients in both mRNA and viral vector COVID-19 vaccines (administered in the United States) are discarded from the body once antibodies are produced. These vaccines deliver genetic material that instructs cells to begin making spike proteins found on the surface of SARS-CoV-2 that causes COVID-19 to produce an immune response.

Pfizer didn’t comment on the findings of the Swedish study and said only that its mRNA vaccine does not alter the human genome.

“Our COVID-19 vaccine does not alter the DNA sequence of a human cell,” a Pfizer spokesperson told The Epoch Times in an email. “It only presents the body with the instructions to build immunity.”

More than 215 million or 64.9 percent of Americans are fully vaccinated as of Feb. 28, with 94 million having received a booster dose.

Autoimmune Disorders

The Swedish study also found spike proteins expressed on the surface of the liver cells that researchers say may be targeted by the immune system and possibly cause autoimmune hepatitis, as “there [have] been case reports on individuals who developed autoimmune hepatitis after BNT162b2 vaccination.”

The authors of the first reported case of a healthy 35-year-old female who developed autoimmune hepatitis a week after her first dose of the Pfizer COVID-19 vaccine said that there is a possibility that “spike-directed antibodies induced by vaccination may also trigger autoimmune conditions in predisposed individuals” as it has been shown that “severe cases of SARS-CoV-2 infection are characterized by an autoinflammatory dysregulation that contributes to tissue damage,” which the virus’s spike protein appears to be responsible for.

Spike proteins may circulate in the body after an infection or injection with a COVID-19 vaccine. It was assumed that the vaccine’s spike protein would remain mostly at the injection site and last up to several weeks like other proteins produced in the body. But studies are showing that is not the case.

The Japanese regulatory agency’s biodistribution study  of the Pfizer vaccine showed that some of the mRNAs moved from the injection site and through the bloodstream, and were found in various organs such as the liver, spleen, adrenal glands, and ovaries of rats 48 hours following injection.

In a different study, the spike proteins made in the body after receiving a Pfizer COVID-19 shot have been found on tiny membrane vesicles called exosomes—that mediate cell-to-cell communication by transferring genetic materials to other cells—for at least four months after the second vaccine dose.

The persistence of the spike protein in the body “raises the prospect of sustained inflammation within and damage to organs which express the spike protein,” according to experts at Doctors for COVID Ethics, an organization consisting of physicians and scientists “seeking to uphold medical ethics, patient safety, and human rights in response to COVID-19.”

“As long as the spike protein can be detected on cell-derived membrane vesicles, the immune system will be attacking the cells that release these vesicles,” they said.

Dr. Peter McCullough, an internist, cardiologist, and epidemiologist, wrote on Twitter that the Swedish study’s findings have “enormous implications of permanent chromosomal change and long-term constitutive spike synthesis driving the pathogenesis of a whole new genre of chronic disease.”

Whether the findings of the study will occur in living organisms or if the DNA converted from the vaccine’s mRNA will integrate with the cell’s genome is unknown. The authors said more investigations are needed, including in whole living organisms such as animals, to better understand the potential effects of the mRNA vaccine.

“At this stage, we do not know if DNA reverse transcribed from BNT162b2 is integrated into the cell genome. Further studies are needed to demonstrate the effect of BNT162b2 on genomic integrity, including whole genome sequencing of cells exposed to BNT162b2, as well as tissues from human subjects who received BNT162b2 vaccination,” the authors said.

 

الدراسة أثبتت أن لقاح فايزر ضد كورونا متحور أميكرون يتلاشى بعد عدة أسابيع قليلة!!!!

 

Pfizer’s COVID Vaccine Protection Against Omicron Fades After a Few Weeks: Study

By Jack Phillips

 

May 16, 2022 Updated: May 16, 2022

biggersmaller 

الدراسة أثبتت أن لقاح فايزر ضد كورونا متحور أميكرون يتلاشى بعد عدة أسابيع قليلة

The protection afforded against the Omicron coronavirus variant fades quickly after a second and third dose of Pfizer–BioNtech’s COVID-19 vaccine, according to a peer-reviewed study published in the JAMA Network.

الحماية الممنوحة ضد متغير فيروس كورونا أوميكرون تتلاشى بسرعة بعد الجرعة الثانية والثالثة من لقاح  COVID-19 من شركة  فايزر Pfizer – BioNtech ، وفقًا لدراسة تمت مراجعتها من قِبل النشرات العلمية ونشرت في شبكة JAMA.

A Danish study published in the JAMA Network on May 13 found that there was a rapid decline in Omicron-specific serum neutralizing antibodies only a few weeks after the administration of the second and third doses of the vaccine.

وجدت دراسة دنماركية نُشرت في شبكة JAMA في 13 مايو أن هناك انخفاضًا سريعًا في الأجسام المضادة المعادلة لمصل أوميكرون بعد أسابيع قليلة فقط من إعطاء الجرعتين الثانية والثالثة من اللقاح.

 

The study evaluated 128 adults who were vaccinated, and of that number, 73 people received two doses of the Pfizer vaccine, and 55 people received three doses between January 2021 and October 2021 or were previously infected before February 2021, and then vaccinated.

قامت الدراسة بتقييم 128 بالغًا تم تطعيمهم ، ومن هذا العدد تلقى 73 شخصًا جرعتين من لقاح فايزر ، وتلقى 55 شخصًا ثلاث جرعات بين يناير 2021 وأكتوبر 2021 أو أصيبوا سابقًا قبل فبراير 2021 ، ثم تم تطعيمهم.

“Our study found a rapid decline in Omicron-specific serum neutralizing antibody titers only a few weeks after the second and third doses,” an abstract of the study reads. “The observed decrease in population neutralizing antibody titers corresponds to the decrease in vaccine efficacy against polymerase chain reaction–confirmed Omicron infection in Denmark and symptomatic Omicron infection in the United Kingdom.”

ملخص الدراسة: "وجدت دراستنا انخفاضًا سريعًا في عيار الأجسام المضادة الخاصة بأوميكرون المصل المحدد بعد أسابيع قليلة فقط من الجرعتين الثانية والثالثة". "الانخفاض الملحوظ في عيار الأجسام المضادة المعادلة للسكان يتوافق مع انخفاض فعالية اللقاح ضد تفاعل البلمرة المتسلسل - عدوى Omicron المؤكدة في الدنمارك وعدوى Omicron المصحوبة بأعراض في المملكة المتحدة."

The antibody levels, which are associated with protection against future infections, dropped within a few weeks of getting the vaccine doses. They were also much lower than the antibodies specific to the Delta and original COVID-19 strains, according to the study.

انخفضت مستويات الأجسام المضادة ، المرتبطة بالحماية من العدوى المستقبلية ، في غضون أسابيع قليلة من الحصول على جرعات اللقاح. كانت أيضًا أقل بكثير من الأجسام المضادة الخاصة بدلتا وسلالات COVID-19 الأصلية ، وفقًا للدراسة.

The proportion of Omicron-specific antibodies fell to 53 percent between the eighth and tenth week from 76 percent four weeks after the second dose. At weeks 12 to 14, these levels dropped even more to only 19 percent, according to the study.

انخفضت نسبة الأجسام المضادة الخاصة بأوميكرون إلى 53 بالمائة بين الأسبوعين الثامن والعاشر من 76 بالمائة بعد أربعة أسابيع من الجرعة الثانية. في الأسابيع من 12 إلى 14 ، انخفضت هذه المستويات أكثر إلى 19 في المائة فقط ، وفقًا للدراسة.

 

Those antibodies increased with a third dose, increasing 21-fold three weeks after the dose before dropping to eightfold at week four. But with the third dose, antibody levels dropped as early as three weeks, falling 5.4-fold between the third and eighth week, the researchers said.

زادت هذه الأجسام المضادة بجرعة ثالثة ، وزادت بمقدار 21 ضعفًا بعد ثلاثة أسابيع من الجرعة قبل أن تنخفض إلى ثمانية أضعاف في الأسبوع الرابع. لكن مع الجرعة الثالثة ، انخفضت مستويات الأجسام المضادة في وقت مبكر يصل إلى ثلاثة أسابيع ، وانخفضت بمقدار 5.4 أضعاف بين الأسبوعين الثالث والثامن ، كما قال الباحثون.

They concluded that it may be needed to provide additional booster doses to combat the Omicron variant, which emerged last fall, primarily among older individuals.

وخلصوا إلى أنه قد تكون هناك حاجة لتوفير جرعات معززة إضافية لمكافحة متغير أوميكرون  الذي ظهر في الخريف الماضي ، بشكل أساسي بين الأفراد الأكبر سنًا.

However, a study from Israeli researchers published in early April in the New England Journal of Medicine found that a fourth dose, or a second booster, of the Pfizer vaccine, doesn’t offer strong protection.

“Overall, these analyses provided evidence for the effectiveness of a fourth vaccine dose against severe illness caused by the omicron variant, as compared with a third dose administered more than 4 months earlier,” the study’s authors wrote at the time, after analyzing data from the Israeli Ministry of Health. “For confirmed infection, a fourth dose appeared to provide only short-term protection and a modest absolute benefit.”

عجيب أمر شركات اللقاحات! اللقاح فعال لمتحور أوميكرون ، بعدها بكام سطر مش أكيد فاعليته بعدها بكام سطر ممكن عمل لقاح جديد خاص للمتحور في خلال 6 أسابيع! أيهم الصحيح

 

Pfizer says booster dose of vaccine protects against omicron variant

A booster dose of the Pfizer-BioNTech Covid-19 vaccine appears to provide strong protection against the omicron variant, the companies announced Wednesday.

أعلنت شركة فايزر يوم الأربعاء أن الجرعة المعززة من لقاحها بايو إن تيك كوفيد-19 يوفر حماية قوية لمتحور أوميكرون

They said a third dose of their vaccine provides a similar level of neutralizing antibodies to omicron, comparable to two doses against the original coronavirus and other variants that have emerged.

Blood samples from those who received only the primary series of the vaccine, on average, did see a 25-fold drop in antibodies against the new variant, indicating that two doses of the vaccine may not be sufficient to protect against infection with omicron.

عينات الدم التي تم أخذها من الأشخاص الذين حصلوا على اللقاح بالسلسلة الأولى له ، أظهرت أنخفاضاً في الأجسام المضادة 25 ضعفاً للمتحور الجديد ، مما يشير إلى أن الجرعتين من اللقاح قد لا تكون كافية للحماية  والوقاية من الأصابة بمتحور أوميكرون

As the highly mutated omicron variant, first identified in South Africa, spreads around the globe, scientists are racing to determine what whether the available vaccines will work against it.


The companies said the results are preliminary. The findings were detailed in a press release, and the full data have not yet been made available for other scientists to scrutinize.

But lab studies are only one piece of the puzzle. Other data are also needed to determine whether a new vaccine is needed. Scientists need to understand transmissible the omicron variant is (early indications suggest it's more contagious than the delta variant) as well as how sick it makes people (early data suggests the illness caused by the variant is milder).

المعلومات الأخرى سوف تحدد هل نحتاج  لقاح جديد

The results from Pfizer-BioNTech are the first announced by vaccine makers. Tuesday, a South Africa research institute also released lab results on how the Pfizer vaccine fared against omicron, showing about a fortyfold reduction in vaccine-induced antibodies that could neutralize the new variant. That study didn't look at booster shots, however.

Pfizer-BioNTech has previously said it could develop a variant-specific vaccine within six weeks and ship initial batches within 100 days.

وسبق أن أعلنت شركة فايزر أنها قد تقوم بتطوير لقاح محدد للمتحور خلال ستة أسابيع وتقوم بتوريد دفعات أولية خلال 100 يوم

Moderna and Johnson & Johnson are expected to release lab results from the omicron variant in the coming days. Academic research institutions are also looking into how well the vaccine works against omicron.

https://www.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html

 

What We Know about Omicron

Infection and Spread

• How easily does Omicron spread? The Omicron variant likely will spread more easily than the original SARS-CoV-2 virus and how easily Omicron spreads compared to Delta remains unknown. CDC expects that anyone with Omicron infection can spread the virus to others, even if they are vaccinated or don’t have symptoms.
• من المحتمل أن ينتشر متحور اوميكرون بسهولة أكبر من فيروس كوفيد-19 الأصلي وبالنسبة لمدى سهولة أنتشار أوميكرون مقارنة ب متحور دلتا، لازال غير معروف للعلماء، ويتوقع مركز التحكم والسيطرة على الأمراض أن آي شخص مصاب بعدوى اوميكرون يمكن أن ينشر الفيروس للأخرين حتى لمن حصل على التطعيمين أو من لا يظهر عليه أعراض

• Will Omicron cause more severe illness? More data are needed to know if Omicron infections, and especially reinfections and breakthrough infections in people who are fully vaccinated, cause more severe illness or death than infection with other variants.
• هناك حاجة للمزيدمن المعلومات والبيانات لمعرفة ما إذا كانت عدوى أميكرون العدوى والإصابات في الأشخاص الذين تم تطعيمهم تسبب مرضاً شديداً أو وفاة بطريقة أكبر من المتحورات السابقة
• Will vaccines work against Omicron? Current vaccines are expected to protect against severe illness, hospitalizations, and deaths due to infection with the Omicron variant. However, breakthrough infections in people who are fully vaccinated are likely to occur. With other variants, like Delta, vaccines have remained effective at preventing severe illness, hospitalizations, and death. The recent emergence of Omicron further emphasizes the importance of vaccination and boosters.
• Will treatments work against Omicron? Scientists are working to determine how well existing treatments for COVID-19 work. Based on the changed genetic make-up of Omicron, some treatments are likely to remain effective while others may be less effective.
• هل ستكون العلاجات واللقاحات الحالية فعالة مع متحور أميكرون؟
• مازال العلماء يعملون على تحديد مدى نجاح العلاجات الحالية ل كوفيد-19 بناءً على التركيب الجيني المتغير لاوميكرون ، ومن المرجح أن تظل بعض تلك العلاجات فعالة بينما قد يكون البعض الآخر أقل فاعلية. ومن عندي أول لا فاعليه لها على الإطلاق

We have the Tools to Fight Omicron

Vaccines remain the best public health measure to protect people from COVID-19, slow transmission, and reduce the likelihood of new variants emerging. COVID-19 vaccines are highly effective at preventing severe illness, hospitalizations, and death. Scientists are currently investigating Omicron, including how protected fully vaccinated people will be against infection, hospitalization, and death. CDC recommends that everyone 5 years and older protect themselves from COVID-19 by getting fully vaccinated. CDC recommends that everyone ages 18 years and older should get a booster shot at least two months after their initial J&J/Janssen vaccine or six months after completing their primary COVID-19 vaccination series of Pfizer-BioNTech or Moderna.

Masks offer protection against all variants. CDC continues to recommend wearing a mask in public indoor settings in areas of substantial or high community transmission, regardless of vaccination status. CDC provides advice about masks for people who want to learn more about what type of mask is right for them depending on their circumstances.

Tests can tell you if you are currently infected with COVID-19. Two types of tests are used to test for current infection: nucleic acid amplification tests (NAATs) and antigen tests. NAAT and antigen tests can only tell you if you have a current infection. Individuals can use the COVID-19 Viral Testing Tool to help determine what kind of test to seek. Additional tests would be needed to determine if your infection was caused by Omicron. Visit your state, tribal, local, or territorial health department’s website to look for the latest local information on testing.

Self-tests can be used at home or anywhere, are easy to use, and produce rapid results. If your self-test has a positive result, stay home or isolate for 10 days, wear a mask if you have contact with others, and call your healthcare provider. If you have any questions about your self-test result, call your healthcare provider or public health department.

Until we know more about the risk of Omicron, it is important to use all tools available to protect yourself and others.

What CDC is Doing to Learn about Omicron

Virus Characteristics

CDC scientists are working with partners to gather data and virus samples that can be studied to answer important questions about the Omicron variant. Scientific experiments have already started. CDC will provide updates as soon as possible.

Variant Surveillance

In the United States, CDC uses genomic surveillance to track variants of SARS-CoV-2, the virus that causes COVID-19 to more quickly identify and act upon these findings to best protect the public’s health. CDC established multiple ways to connect and share genomic sequence data being produced by CDC, public health laboratories, and commercial diagnostic laboratories within publicly accessible databases maintained by the National Center for Biotechnology Informationexternal icon (NCBI) and the Global Initiative on Sharing Avian Influenza Dataexternal icon (GISAID). CDC’s national genomic surveillance can detect a variant that is circulating at 0.1% frequency with 99% statistical confidence.

 

شرح فيديو بسيط الأول إذا تعتقد أو تعلم أنك مصاب بكوفيد 19 ؟ الثاني إذا علمت أنك مصاب بكوفيد 19 ولا يوجد أعراض؟ الثالث الفرق بين الحجر الصحي والعزل؟

 

الله المستعان ، الجرعة المحفزة أو المنشطة أو الجرعة الثالثة! آي كان الأسم أصبحت ضرورة ثم الآن التركيز على فايزر جرعة تنشيطية أو مودرنا نصف جرعة! ولا كلام على إسترازنكا

مع قدوم فصل الخريف والشتاء يتسابق العالم في محاولات مواجهة الأنفلونزا الموسمية التي يؤخذ لها لقاح والجرعة المنشطة أو الثالثة

(وليست الأخيرة) لكوفيد 19 ونحن في الموجة (التحور الرابع مو)

اللافت للنظر أن الجميع يأخذ إسرائيل التي تعتبر من أفضل دول العالم في موضوع اللقاح للمواطنين نموذجا يحتذى به حيث التجارب والإرشادات والملاحظات تخرج منها أولاً بل أمريكا تأخذ بقولهم!! والله المستعان ، ثم الملاحظة الثانية أنه تم الأعتراف رسمياً بأن اللقاح تقل فاعليته وقد تنعدم بعد ستة أشهر ، الملاحظة الثالثة هي أن الجرعة الثالثة أو ما يسمى بالتنشيطية تأخذ بالإعتبار أخطاء ونتائج العامين الماضيين ، فالجميع يحاول أن تكون الجرعة من فايزر كاملة أو نصف جرعة من موديرنا (لأن الأعراض للنصف الجرعة أقل) والأبتعاد عن أن تكون الجرعة المنشطة من أسترازنكا والملاحظة الأخيرة هي الجميع يخزن الللقاحات طبعا الدول الغنية ولا يلتفت إلى الدول الفقيرة! والله المستعان كذلك لا كلام على لقاحات الصين وغيرها من اللقاحات التي تكاد تكون معروفة إلا في

https://www.dailymail.co.uk/news/article-9988825/Booster-vaccines-50s.html بعض الدول العربية هذا من مقال في الديلي ميل البريطانية

Government's vaccine advisory panel has recommended third doses be dished out to some 30million people
Plans approved on the back of real-world data in Israel and elsewhere suggesting immunity wanes in months
Britons who are eligible will be given Pfizer's vaccine or a half-dose of the Moderna vaccine

The Government’s vaccine advisory panel recommended a third dose for roughly 30million people aged 50 and over who received their second injection at least six months ago.



Members of the Joint Committee on Vaccination and Immunisation (JCVI) approved the plans on the back of growing real-world data in Israel and elsewhere, as well as a major British study, which suggested vaccine-induced immunity wanes within months.




Britons who are eligible will be given the Pfizer vaccine in the first instance, no matter which jab they were originally immunised with. When there are supply constraints, the Moderna vaccine will be offered as a booster in the form of a half dose.

Officials said there was more evidence that the mRNA vaccines were safe and effective when given as a third dose, which is why they are not recommending AstraZeneca's.

Moderna's is being recommended as a half dose because the lower dosage is associated with fewer side effects and still produces a strong immune response, the JCVI said.

People who are invited for their booster Covid vaccine will be able to get their flu jab at the same time, in the opposite arm.














Professor Wei Shen Lim, of the Joint Committee on Vaccination and Immunisation, said the recommendation of at least a six-month gap between the second jab and a booster shot was an attempt to find an immunity 'sweet spot'.


'We want to suggest a six-month limit as a lower limit because we don’t want people to feel they need to rush to have this booster dose,' he told a Downing Street press conference.

'Getting a booster dose too early might mean getting a dose when they don’t actually need to have vaccination because they still have a high level of protection.

'And, as we have seen with the first and second dose, it may be that a longer interval to the third booster dose may actually be beneficial in the longer term.

'On the other hand, we don’t want to wait too long before offering a booster dose, so trying to find a sweet spot between going too soon and going too late we are suggesting that the booster dose is given no earlier than six months after the second dose.'




Professor Lim said it was preferable for people to get an mRNA vaccine as a booster — such as those made by Pfizer and Moderna — because there was more evidence compared to the AstraZeneca jabs that these are safe and effective.

He told the briefing: 'The AstraZeneca vaccine obviously is a very good vaccine for its primary cause.

'We’ve seen data that suggests that the mRNA vaccines given, whatever the primary cause for the vaccination is, gives a very good boost.

كل فترة يظهر شئ جديد فايزر مشاكل بالقلب استرازنكا تجلطات بالدم موديرنا عضلة القلب والآن في اليابان إيقاف مودرنا أحترازياً لوفاة شخصين بعد الجرعة الثانية!

 

Two die in Japan after shots from

 suspended Moderna vaccines

 - Japan govt

TOKYO, Aug 28 (Reuters) - Two people died after receiving Moderna COVID-19 vaccine shots that were among lots later suspended following the discovery of contaminants, Japan's health ministry said on Saturday.

The men in their 30s died this month within days of receiving their second Moderna doses, the ministry said in a release. Each had a shot from one of three manufacturing lots suspended on Thursday. The cause of the deaths is still being investigated.

Japan halted the use of 1.63 million Moderna doses https://www.reuters.com/world/asia-pacific/japan-withdraws-16-mln-moderna-covid-19-vaccine-doses-over-contamination-nikkei-2021-08-25 shipped to 863 vaccination centres nationwide, more than a week after the domestic distributor, Takeda Pharmaceutical, received reports of contaminants in some vials.

The government and Moderna had said no safety or efficacy issues had been identified and the suspension was just a precaution.


The contaminant is believed to be metallic particles, Japanese public broadcaster NHK reported, citing health ministry sources.

خطوة خطوة للجرعة الثالثة ثم الرابعة ثم كل كام شهر أم كل سنة

الجميع ممن يتابع موضوع كورونا والتطعيمات قد يلاحظ أننا نؤخذ خطوة خطوة لشئ ما! الأول التطعيم مرتين ثم جرعة ثالثة للجهاز الطبي والعاملين فية وكبار السن ثم جرعة ثالثة لمن المناعة لديهم ضعيفة ثم لمن هم ضعيفة أو متوسطة؟؟؟ ثم نكتشف من فترة أن فاعلية التطعيم غير معروف مدة فاعليتها تتناقص بعد ثلاثة إلى ستة أشهر لتصبح 81% تقريباً ثم ماذا بعد ستة أشهر أخرى؟؟؟ شركات الأدوية خاصة الخاصة باللقاحات كسبت مليارات من هذا الأمر و المتخصصون مازال الكثير منهم يعترف أنه لا يعرف مدى صلاحية وفاعلية أغلب اللقاحات ومع هذا غيرنا من مناعة القطيع إلى المناعة المجتمعية (أسم أفضل شوية فنحن لسنا قطيعاً من الأغنام) ثم لقاح كذا يسبب جلطات دموية ولقاح كذا يسبب ضعف في عضلة القلب ، ولقاح كذا يسبب الوفاة وأعراض خطيرة لبعض الناس؟؟ من يقول التي تتناول حبوب منع الحمل وآخر يقول لديهم مشاكل صحية وووو بل أن نسبة 70% من المصابين بالمتحور دلتا الجديد ممن أخذ الجرعتين! سبحانك ربي أقوال كثيرة لأننا مازلنا في التجارب بعد عامين من المرض (سبحانك ربي) فيرس لا يرى بالعين المجردة مصنوع من الأنسان وتم تسريبه؟ كما يقال (وعندي لا فرق كلاهما بأقدار الله)لا يعرف الأنسان أن يعالجه!!! ليس مهرب وإنما من الخفافيش!!! أيضاً سبحانك ربي ماذا فعل بالعالم العبقري الذي طلع القمر ويستكشف الكواكب حولنا وأخر ما وصلت اليه التكنولوجيا والتنصت والأختراق وحروب الكترونية ووو ولا يمكنه فعل شئ .بالتأكيد أنا لست متخصص وإنما قارئ 

 وأكتب غالباً لنفسي لأسجل بعض ما يدور في خلدي عن هذا الأمر 

سبحان الله العظيم  سبحان ربي العظيم الوهاب سبحان ربي الأعلى الوهاب

 NOTICE: CDC now recommends that people whose immune systems are compromised moderately to severely should receive an additional dose of mRNA COVID-19 vaccine after the initial 2 doses.

 Widespread vaccination is a critical tool to help stop the pandemic. Read CDC’s statement.

 What You Need to Know

 People who are moderately to severely immunocompromised are especially vulnerable to COVID-19 because they are more at risk of serious, prolonged illness. People who have compromised immune systems may benefit from an additional dose to make sure they have enough protection against COVID-19. CDC recommends people who are moderately to severely immunocompromised should receive an additional dose of mRNA COVID-19 vaccine after the initial 2 doses. CDC recommends that people with moderately to severely compromised immune systems receive an additional dose of mRNA COVID-19 vaccine at least 28 days after a second dose of Pfizer-BioNTech COVID-19 vaccine or Moderna COVID-19 vaccine. CDC does not recommend additional doses or booster shots for any other population at this time. Data on Decreased Immune Response Among Immunocompromised People People who are moderately to severely immunocompromised make up about 3% of the adult population and are especially vulnerable to COVID-19 because they are more at risk of serious, prolonged illness. Studies indicate some immunocompromised people don’t always build the same level of immunity after vaccination the way non-immunocompromised people do, and may benefit from an additional dose to ensure adequate protection against COVID-19. In small studies pdf icon[2 MB, 36 Pages], fully vaccinated immunocompromised people have accounted for a large proportion of hospitalized “breakthrough cases,” and that suggests immunocompromised people are more likely to transmit the virus to household contacts.

 Who Needs an Additional COVID-19 Vaccine? 

Currently, CDC is recommending that moderately to severely immunocompromised people receive an additional dose. This includes people who have: 

* Been receiving active cancer treatment for tumors or cancers of the blood 

* Received an organ transplant and are taking medicine to suppress the immune system 

* Received a stem cell transplant within the last 2 years or are taking medicine to suppress the immune system

 * Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)

 * Advanced or untreated HIV infection Active treatment with high-dose corticosteroids or other drugs that may suppress your immune response

Booster shots هل سيحتاج الناس إلى جرعة ثالثة؟ الآن يبحثوا الجرعة الثالثة للعاملين بالمجال الطبي وكبار السن!

 حيث أنهم لا يعلمو مدى تحصين اللقاح لإخذه والمدة التي ينتهي فيها التأثير ويعود الشخص عرضة للمرض مره أخرى أو يبدأ في أخذ جرعات من اللقاح جديدة! لتأمين دوام الوقاية تماماً مثل لقاحات الأنفلونزا هنا يتكلموا عن الجرعة الثالثة أو المنشطة !! كذلك سيتم الأعتراف قريباً بأن لقاحات فايزر وموديرنا تسبب في بعض الأشخاص أعراض قد تكون مميتة في عضلة القلب

Booster shots may NOT be needed this autumn but the elderly and NHS will be first in line if they are, claims one of No10's top vaccine advisers 

Booster Covid vaccines may not be needed this autumn, one of the Government's top experts claimed today.

Professor Adam Finn, from the Joint Committee on Vaccination and Immunisation (JCVI) - which advises No10, insisted top-up jabs may well be required for the very elderly and NHS workers.

But he admitted there was still a 'high level of uncertainty' over whether they would be necessary for millions of other Brits.

Scientists had expected the protection given by vaccines to begin to wear off over time but they don't yet know how long immunity from Covid jabs lasts for.

Influenza vaccines are needed every winter because the virus is constantly evolving to beat the human immune system. 

Coronaviruses tend to mutate slower and academics have claimed they've yet to see any proof of waning immunity in vaccinated Britons.

Last month Matt Hancock announced at a Downing St press conference scientists were beginning trials of a third jab to check if it offers better protection.

Millions more vaccine doses than necessary have been bought by the Government and a giant order of 60million more Pfizer doses in April was earmarked for a top-up campaign in the autumn. 

==============================

British health chiefs could soon issue a warning that Pfizer and Moderna's Covid jabs are linked to heart issues in extremely rare cases, experts believe. 

Fears about the two jabs causing myocarditis have grown in recent weeks, following a string of cases in young adults and children in Israel and the US.

American regulators have already accepted there is a 'likely link' between the heart condition and the vaccines, and will add warnings about the potential complication on information sheets given to the public.

Israel's Health Ministry has said the Pfizer vaccine, the only jab it is using in its rollout, is the 'probable' cause in a tiny number of cases. 

Last week the Medicines and Healthcare products Regulatory Agency (MHRA), which polices the safety of drugs in the UK, said rates of myocarditis among vaccinated adults were 'similar or below' expected levels.

But last night, MailOnline can reveal the watchdog dropped all mention of how often the complication was occurring. Instead, it just updated its weekly summary to say cases were 'very rare' and 'typically mild'.

One cardiologist said he believed it the change in tone may signal that the body was going to accept a link between the two vaccines and myocarditis. 

Other experts warned it further complicated the debate about vaccinating children in Britain. 

============================================================

WHAT IS MYOCARDITIS? 

Myocarditis is an inflammation of the heart muscle. There are no specific causes of the condition but it is usually triggered by a virus.

Some of the most common infections which cause myocarditis, are those called adenovirus and Coxsackie B.

It can be caused by the common cold, hepatitis B and C, and herpes simplex virus. 

The most common symptoms of the condition include chest pain, a fever, a fast heartbeat, tiredness and shortness of breath.

If the inflammation damages the heart muscle or the fibres that conduct electrical pulses to the heart, complications can develop.

They can develop quickly, and include sudden loss of consciousness, an abnormally fast, slow or irregular heartbeat.

In very severe cases the condition is fatal, causing heart failure or sudden death. The inflammation enlarges the heart and creates scar tissue, forcing it to work harder and therefore making it weaker.

In most cases of viral myocarditis, the illness goes away and there are no complications. 

But in rare cases when inflammation is severe, there can be damage to the heart which needs monitoring and possibly a heart transplant.

Myocarditis can reoccur, but there is no known way to prevent this. The risk of recurrence is low, around 10 to 15 per cent, according to Myocarditis Foundation.

It is difficult to gauge the prevalence of myocarditis because there is no widely available test for it.

In 2010, approximately 400,000 people died of heart muscle disease - cardiomyopathy that includes myocarditis - worldwide.

Expert consensus opinion estimates that up to 40 per cent of dilated cardiomyopathy results from myocarditis, according to the National Organisation for Rare Disorders.

الموضوع في دايلي ميل

https://www.dailymail.co.uk/news/article-9725051/UK-health-chiefs-say-rates-myocarditis-higher-expected-amoung-young-adults.html

AstraZeneca & Pfizer's jabs some problems (quoted from https://www.dailymail.co.uk/news/article-9712333/

 

Four British men develop potentially deadly Guillain-Barré syndrome just days after having AstraZeneca's Covid jab

• Four men in Nottingham developed Guillain-Barré syndrome after a Covid jab
• Cases linked to AstraZeneca's vaccine but scientists have not identified cause
• Six cases of the syndrome were also identified in Australia and seven in India

Four British men have developed a potentially life-threatening condition just days after having AstraZeneca's Covid vaccine. 

The recipients developed Guillain-Barré syndrome, which can cause paralysis and leave patients in crippling pain. 

All four cases were spotted in the Nottingham area, where around 700,000 people have had the British firm's coronavirus jab. 

British health chiefs have yet to offer a public breakdown of how many cases of the syndrome have been spotted in vaccine recipients across the entire country. 

But a similar link has been spotted in both Australia and India, where AstraZeneca's vaccine is also being dished out. It is also a known rare side effect of flu and HPV jabs.

AstraZeneca's jab — which is given as a double-dose — has also been heavily linked to deadly blood clots in younger adults. 

For that reason, UK drug watchdogs have recommended under-40s, who face a tiny risk of falling seriously ill with Covid, get alternative jabs.

But data is now also emerging that shows Pfizer's jab — the other main option being administered in the UK — may cause heart inflammation. 

Cases of Guillain-Barre syndrome after AstraZeneca's vaccine were described in two separate studies in the journal Annals of Neurology.

The complication — normally triggered by an infection — usually occurs in around one in 100,000 people in the UK and US.

What is Guillain-Barre syndrome?

Guillain–Barré syndrome is a rare disorder in which the immune system goes into overdrive and the body attack its own nerves.

Common symptoms of the rare condition include weakness and tingling in the limbs. 

As patients' conditions worsen, this can lead to parts of the body — or in some cases the whole body — being paralysed.

The syndrome is rare, affecting about one in 100,000 annually in the UK and US.

Fewer than 20,000 cases are diagnosed per year in the US, according to the National Institute of Neurological Disorders and Stroke. 

Doctors say it is often triggered by a viral or bacterial illness, such as Campylobacter jejuni. 

There is no cure. Treatment focuses on restoring the nervous system.

It can be fatal if it involves the respiratory muscles. 

But doctors in India who also uncovered the link say it was occurring up to 10 times more than expected.

One of the articles published in the journal broke down the cases spotted in Nottingham, which all occurred within ten days of each other. 

Symptoms began 11 to 22 days after the first jab and all of the four men were aged between 20 and 57.

One had no relevant medical history. The three others others had ulcerative colitis, asthma and high blood pressure.

None had been infected with Covid. They were treated with antibodies and steroid pills.

Dr Christopher Allen, a clinical neuroscientist at Nottingham University, who wrote the article, admitted they cannot be certain the jab caused the neurological illness and it could have happened by chance.

But it demonstrates the need for 'robust post-vaccination surveillance,' he said. And he added vaccines currently deployed are 'very safe'.

Dr Allen added the reaction may be 'a cross-reactive immune response to the SARS-CoV-2 spike protein', causing the immune system to overreact and the body to attack its own nerves. 

Dr Allen said if the condition is caused by AstraZeneca's vaccine, it will be because spike proteins contained in the firm's viral vector technology.

Pfizer's and Moderna's MRNA vaccines do not contain the same spike proteins, so are unlikely to see similar links to the syndrome.

The second paper by neurologists at the Aster Medcity hospital in Kochi, Kerala, identified seven cases of severe Guillain-Barré syndrome.

They were struck down within a fortnight of receiving the first AstraZeneca vaccine.

Lead author Dr Boby Varkey Maramattom said rates of the condition were between 1.4 and 10-fold higher than would normally be expected. 

And the patients suffered 'unusually severe' facial weakness — one of the symptoms of the condition.

Four of the cases involved women aged 40 to 70 years — three of whom required mechanical ventilation.

Nerve damage around the face and head occurred in four patients — which happens in less than five per cent of Guillain-Barré syndrome cases.

Dr Maramattom said while the findings suggested the vaccine could be to blame a clear link had been proven and it is 'unlikely' the jabs had triggered the syndrome in all cases.

The benefits of vaccination also 'substantially outweigh the risk of this relatively rare outcome,' he said.

Covid itself is also linked to Guillain-Barré syndrome, with the virus believed to have triggered the condition in a man, 54, in New Jersey in April 2020.